Aggressive statin therapy goals needed to drive down apoB levels

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1652, 2008-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relating statin therapy to C-reactive protein levels

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 9, 2005-08 ,pp. : 1597-1600

Informa Healthcare

Access to resources Recommend Favorite

Statin Therapy

Current Pharmaceutical Design, Vol. 18, Iss. 38, 2012-12 ,pp. : 6284-6290

Bentham Science Publishers

Access to resources Recommend Favorite

Benefits of statin therapy due to reduction in LDL-cholesterol levels

Inpharma, Vol. 1, Iss. 1508, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

By Bays Harold E.

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 3, 2012-06 ,pp. : 197-206

Adis International

Access to resources Recommend Favorite

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

By Sahebkar Amirhossein Watts Gerald

Cardiovascular Drugs and Therapy, Vol. 27, Iss. 6, 2013-12 ,pp. : 559-567

Springer Publishing Company

Access to resources Recommend Favorite